Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors : Impact on Efficacy and Survival
BACKGROUND: Geriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection.
METHODS: We built a multicenter, international retrospective study of 885 patients (<80 years: n = 417, 47.12%; ≥80 years: n = 468, 52.88%) with different tumor types treated with ICIs between 2011 and 2021 from 11 academic centers in the U.S. and Europe. The main outcome measures were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) stratified by age and circulating inflammatory levels (neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII)).
RESULTS: Patients ≥80 years with low NLR (NLR-L) and SII (SII-L) had significantly higher ORR (vs. high NLR [NLR-H], p < 0.01 and SII-H, p < 0.05, respectively). At median follow-ups (13.03 months), and compared to SII-H, patients with SII-L had significantly longer median PFS and OS in patients <80 (p < 0.001), and ≥80 years (p < 0.001). SII-L was independently associated with longer PFS and OS (HR: 0.61 and 0.62, respectively, p < 0.01).
CONCLUSION: Lower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 20 vom: 19. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choucair, Khalil [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 30.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15205052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363864369 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363864369 | ||
| 003 | DE-627 | ||
| 005 | 20231226094238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15205052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363864369 | ||
| 035 | |a (NLM)37894419 | ||
| 035 | |a (PII)5052 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choucair, Khalil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors |b Impact on Efficacy and Survival |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Geriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection | ||
| 520 | |a METHODS: We built a multicenter, international retrospective study of 885 patients (<80 years: n = 417, 47.12%; ≥80 years: n = 468, 52.88%) with different tumor types treated with ICIs between 2011 and 2021 from 11 academic centers in the U.S. and Europe. The main outcome measures were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) stratified by age and circulating inflammatory levels (neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII)) | ||
| 520 | |a RESULTS: Patients ≥80 years with low NLR (NLR-L) and SII (SII-L) had significantly higher ORR (vs. high NLR [NLR-H], p < 0.01 and SII-H, p < 0.05, respectively). At median follow-ups (13.03 months), and compared to SII-H, patients with SII-L had significantly longer median PFS and OS in patients <80 (p < 0.001), and ≥80 years (p < 0.001). SII-L was independently associated with longer PFS and OS (HR: 0.61 and 0.62, respectively, p < 0.01) | ||
| 520 | |a CONCLUSION: Lower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a circulating inflammatory markers | |
| 650 | 4 | |a geriatric oncology | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a systemic immune-inflammatory index | |
| 700 | 1 | |a Nebhan, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Hentzen, Stijn |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Giusti, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Filetti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ascierto, Paolo Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vanella, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Galetta, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Catino, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Bzour, Nour |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Azhar |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalcante, Ludimila |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzutilo, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Genova, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bersanelli, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Sebastiano |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Douglas B |e verfasserin |4 aut | |
| 700 | 1 | |a Fulgenzi, Claudia Angela Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Radford, Maluki |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Naqash, Abdul Rafeh |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Anwaar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 20 vom: 19. Okt. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:20 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15205052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 20 |b 19 |c 10 | ||